Aclarion Taps PRIA Healthcare to Boost Nociscan Reimbursement in U.S.
Event summary
- Aclarion partners with PRIA Healthcare to launch a Market Access Program for its AI-driven Nociscan platform.
- Program aims to streamline reimbursement processes and expand commercial adoption in the U.S.
- Nociscan has already secured payer approval from three of the top four private insurance companies in the UK.
- PRIA Healthcare will provide expertise in payer engagement, prior authorization support, and appeals management.
The big picture
Aclarion's partnership with PRIA Healthcare is a strategic move to navigate the complex U.S. reimbursement landscape, following successful payer approvals in the UK. This collaboration aims to bridge the gap between clinical evidence and commercial adoption, addressing a critical bottleneck in the scaling of AI-driven diagnostic tools in spine care. The success of this initiative could set a precedent for other MedTech innovators seeking to expand market access in the U.S.
What we're watching
- Reimbursement Momentum
- How quickly Aclarion can replicate its UK reimbursement success in the more complex U.S. market.
- Commercial Scaling
- Whether the Market Access Program can significantly reduce market access barriers and drive scan volume growth.
- Payer Dynamics
- The pace at which U.S. payers adopt Nociscan, given the platform's clinical and economic evidence.
Related topics